Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    Glyceraldehyde-3-Phosphate Dehydrogenase

    go.drugbank.com/drugs/DB17012
    Experimental

    Categories: Oxidoreductases Acting on Aldehyde or Oxo Group Donors
  2. Drug

    Dilazep

    go.drugbank.com/drugs/DB13715
    Experimental

    Categories: Vasodilators Used in Cardiac Diseases
  3. Drug

    Glycochenodeoxycholic Acid

    go.drugbank.com/drugs/DB02123
    Experimental

    A bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed.

    Categories: N-substituted Glycines, Compounds used in a research, industrial, or household setting
  4. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  5. Drug

    Rotavirus vaccine

    go.drugbank.com/drugs/DB10276
    ApprovedInvestigational

    [Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.[L1117]

  6. Drug

    Maltotetraose

    go.drugbank.com/drugs/DB02237
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

  8. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  9. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  10. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.